EUVIMEDEUVIMED entdecken
Crossref

A pragmatic endoscopic/histological classification of immune checkpoint inhibitor-induced colitis: clinical and transcriptomic correlates

Hajir Ibraheim, Paolo Davide d'Arienzo, Nathan James Dean, Ashish Singh, Balasz Bohar, Thubeena Manickavasagar, Foteini Kalofonou, Mohamed Aboulela, Sree Vadera, Kirsty Ellen Anderson, Dr Michael Campbell, Jacob Lewis und 10 weitere

Clinical Gastroenterology and Hepatology · 2026-11

DOI: 10.1016/j.cgh.2026.10.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Hajir Ibraheim und 21 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London, The Royal Marsden Hospital. Electronic address: h.ibraheim@nhs.net.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Immune checkpoint inhibitors (ICI) improve cancer outcomes but frequently induce ICI-colitis, causing significant morbidity, prolonged immunosuppression, and premature ICI discontinuation. Risk stratification using CTCAE diarrhoea grading is imprecise, highlighting the need for clinically and biologically informed classification. METHODS: Retrospective data from 250 patients at two U.K. centres were analysed. Endoscopic severity was graded by Mayo endoscopic score (MES). Associations were assessed using chi-squared and multivariable analysis. Transcriptomic profiling of colonic biopsies (18 patients, 18 controls) was performed for gene- and pathway-level analyses. RESULTS: Patients were classified into two endoscopic-histological phenotypes: Group 1, mild inflammation (MES 0-1), comprising Group 1a, non-microscopic colitis (69.4%) and Group 1b, microscopic colitis (10.5%); and Group 2, moderate-to-severe colitis (MES 2-3; 20%). Bloody stool, anti-CTLA-4 therapy, and anti-PD-(L)1 plus chemotherapy independently predicted Group 2 (AUC 0.79), which was associated with higher faecal calprotectin, hospitalisation, steroid-refractory disease, and surgery. Group 1b, associated with anti-PD-1(L1) therapy had the mildest phenotype with no bloody stool or grade 4 diarrhoea and fewer hospitalisations. Oral second-generation corticosteroids achieved >80% remission in Group 1. ICI re-challenge led to recurrence in ∼37%, typically of similar or lower severity. Transcriptomic profiling identified a shared inflammatory programme across groups, with Group 2 additionally enriched for VEGF signalling, extracellular matrix remodelling, and epithelial-mesenchymal transition. CONCLUSIONS: Phenotype-driven classification of ICI-colitis captures clinically and biologically meaningful heterogeneity, identifies high-risk patients and informs therapeutic strategies. This framework supports earlier intervention in severe disease while enabling steroid-sparing approaches in lower-risk groups, reducing treatment-related morbidity.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorimmune-related adverse eventimmunotherapy toxicityimmunotherapy-related colitisirAE

Autor:innen und Institutionen

  • Imperial College London, The Royal Marsden Hospital. Electronic address: h.ibraheim@nhs.net.
  • The Royal Marsden Hospital.
  • The Royal Marsden Hospital. Electronic address: nathan.dean@nhs.net.
  • The Royal Marsden Hospital. Electronic address: ashish.singh@rmh.nhs.uk.
  • Imperial College London. Electronic address: balasz.bohar@imperial.ac.uk.
  • The Royal Marsden Hospital. Electronic address: thubeena.manickavasagar@rmh.nhs.uk.

Zitieren

APA

Ibraheim, H., Davide d'Arienzo, P., James Dean, N., Singh, A., Bohar, B., Manickavasagar, T., Kalofonou, F., Aboulela, M., Vadera, S., Ellen Anderson, K., Campbell, D. M., Lewis, J., Muehlschlegel, P., Mullings, S., James Symington, J., Dar, S., Oommen, I., Goldin, R., Alexander, J., …, & Powell, N. (2026). A pragmatic endoscopic/histological classification of immune checkpoint inhibitor-induced colitis: clinical and transcriptomic correlates. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.10.032

Vancouver

Ibraheim H, Davide d'Arienzo P, James Dean N, Singh A, Bohar B, Manickavasagar T, et al. A pragmatic endoscopic/histological classification of immune checkpoint inhibitor-induced colitis: clinical and transcriptomic correlates. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.10.032

BibTeX
@article{Ibraheim2026,
  author = {Ibraheim, Hajir and Davide d'Arienzo, Paolo and James Dean, Nathan and Singh, Ashish and Bohar, Balasz and Manickavasagar, Thubeena and Kalofonou, Foteini and Aboulela, Mohamed and Vadera, Sree and Ellen Anderson, Kirsty and Campbell, Dr Michael and Lewis, Jacob and Muehlschlegel, Paula and Mullings, Stephanie and James Symington, Jake and Dar, Sabeera and Oommen, Irene and Goldin, Robert and Alexander, James and Clare Olsson-Brown, Anna and Young, Kate and Powell, Nick},
  title = {A pragmatic endoscopic/histological classification of immune checkpoint inhibitor-induced colitis: clinical and transcriptomic correlates},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.10.032}
}
Kostenlos starten →